September 20, 2007
Genzyme cancer drug licensed by FDA
By Matthew L. Brown
Genzyme Corp., which is based in Cambridge and has significant operations MetroWest, announced that it and Bayer had been granted a supplemental biologics license by the U.S. Food and Drug Administration for the Campath B-cell chronic lymphocytic leukemia drug.
The FDA also granted single-agent Campath regular approval for the treatment of CLL.
Campath was originally approved by the FDA in 2001 under accelerated approval regulations.
The FDA also granted single-agent Campath regular approval for the treatment of CLL.
Campath was originally approved by the FDA in 2001 under accelerated approval regulations.
WBJ Web Partners
Most Recent
Most Recent
0 Comments